Company / Profit Margin
VYNE Therapeutics Inc. Profit Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-7950.9%
FY2025
5-year range
-7950.9% / -1217.4%
FY2021-FY2025
Trend
-18.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has fluctuated over the past 6 years, ranging from -7950.9% in FY2025 to -1217.4% in FY2021.
Based on SEC 10-K filings.
-7950.9% in FY2025 with a 5-year CAGR of -5887.9%.
Declined from -4865.8% to -7950.9% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -74.5pp
- 5-Year Change
- -5887.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, profit margin decreased 18.5% year-over-year.
- Peak profit margin was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -7950.9% | -18.5% |
| FY2024 | -6710.4% | -37.9% |
| FY2023 | -4865.8% | +38.2% |
| FY2022 | -7876.4% | -547.0% |
| FY2021 | -1217.4% | +41.0% |
| FY2020 | -2062.9% | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026